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Objective: To assess the cost-effectiveness of prucalopride vs. continued laxative
treatment for chronic constipation in patients in the Netherlands in whom laxatives have
failed to provide adequate relief.
Methods: A Markov model was developed to estimate the cost-effectiveness of
prucalopride in patients with chronic constipation receiving standard laxative treatment
from the perspective of Dutch payers in 2011. Data sources included published
prucalopride clinical trials, published Dutch price/tariff lists, and national population
statistics. The model simulated the clinical and economic outcomes associated with
prucalopride vs. standard treatment and had a cycle length of 1 month and a follow-up
time of 1 year. Response to treatment was defined as the proportion of patients who
achieved “normal bowel function”. One-way and probabilistic sensitivity analyses were
conducted to test the robustness of the base case.
Results: In the base case analysis, the cost of prucalopride relative to continued
laxative treatment was e 9015 per quality-adjusted life-year (QALY). Extensive sensitivity
analyses and scenario analyses confirmed that the base case cost-effectiveness estimate
was robust. One-way sensitivity analyses showed that the model was most sensitive
in response to prucalopride; incremental cost-effectiveness ratios ranged from e 6475
to 15,380 per QALY. Probabilistic sensitivity analyses indicated that there is a greater
than 80% probability that prucalopride would be cost-effective compared with continued
standard treatment, assuming a willingness-to-pay threshold of e 20,000 per QALY from
a Dutch societal perspective. A scenario analysis was performed for women only, which
resulted in a cost-effectiveness ratio of e 7773 per QALY.
Conclusion: Prucalopride was cost-effective in a Dutch patient population, as well as
in a women-only subgroup, who had chronic constipation and who obtained inadequate
relief from laxatives.
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Introduction
Constipation is a common condition that may be managed by
self-medication or medical consultation. A consensus definition
of chronic constipation, known as the Rome III criteria, requires
a patient to have experienced at least two of the following symp-
toms over the previous 3 months: fewer than three bowel move-
ments per week; at least 25% of defecations with straining; lumpy
or hard stools; sensation of anorectal obstruction; sensation of
incomplete defecation; and manual manipulation required to
defecate. In addition, the Rome III criteria note that loose stools
are rarely present without the use of laxatives and that a patient’s
symptoms should not meet the defined criteria for irritable bowel
syndrome. Although symptoms of constipation are assessed over
the previous 3 months, patients must be symptomatic for at least
6 months prior to diagnosis to fulfill the criteria for chronic
constipation (Longstreth et al., 2006).
Most patients with chronic constipation should first attempt
lifestyle modifications such as increasing dietary fiber intake to
15–20 g per day, drinking plenty of fluids, and maintaining a reg-
ular exercise program. Despite limited data supporting their use
in clinical practice, these lifestyle changes promote general health
and may improve bowel symptoms in some patients (Chung
et al., 1999; Meshkinpour et al., 1998; Annells and Koch, 2003;
Dukas et al., 2003). The short-term benefits of laxatives are unde-
niable. Laxatives have been shown to increase stool output and
frequency (Passmore et al., 1993) and are relatively straight-
forward to administer. However, the management of chronic
constipation is multifaceted and complex (Dennison et al., 2005).
Chronic use of laxatives may have serious adverse effects
and excessive laxative use has been linked to loss of colonic
motility (Read et al., 1995). Other less severe, but more com-
mon, adverse effects of laxatives include headache, loss of
appetite, and diarrhea (Passmore et al., 1993; Romero et al.,
1996). Duncan et al. (1992) reported that 4% of new cases
of diarrhea among patients seen in gastroenterology clinics
were laxative-induced. All of these consequences may negatively
impact on health-related quality of life (HRQoL) and may pre-
cipitate frequent physician visits and diagnostic testing (Duncan
and Forrest, 2001). Although the study by Duncan et al. was
performed in patients with a recent history of constipation,
we might expect a similar trend in individuals with chronic
constipation.
Chronic constipation is associated with various comorbidities
and, although rare, there are several potentially life-threatening
complications (Singh et al., 2005). The most common complica-
tions are anorectal disorders such as hemorrhoids, fissures, rectal
prolapse, and fecal impaction. Severe refractory chronic constipa-
tion may eventually require a partial colectomy to be performed
(Pikarsky et al., 2001). Such surgical treatment should be con-
sidered only in the most severe cases, for those patients who do
not respond to aggressive medical therapy. It is important to note
that 25% of patients with a partial colectomy may have unsatis-
factory results leading to other complications such as adhesions,
bleeding, thrombosis, and adjacent organ damage (Christiansen
and Rasmussen, 1996). Chronic constipation has an impact on a
patient’s HRQoL, and has economic consequences for both the
affected individual and for society (Dennison et al., 2005; Wald
et al., 2007).
A review by Dennison et al. found that individuals with con-
stipation had lower HRQoL than those without the condition
(Dennison et al., 2005). Constipation symptommeasures include
the Gastrointestinal Symptom Rating Scale, the Elderly Bowel
Symptom Questionnaire, and the Patient Assessment of Con-
stipation Symptoms (PAC-SYM) questionnaire (Dennison et al.,
2005). The PAC-SYM questionnaire is one component of the
Patient Assessment of Constipation (PAC) tool; the other com-
ponent being the PAC-Quality of Life (PAC-QOL) questionnaire,
which is a constipation-specific measure of HRQoL. The two
components are complementary and may be used separately or
together (Frank et al., 1999; Marquis et al., 2005).
Prucalopride belongs to the chemical class of
dihydrobenzofuran-carboxamide derivatives with potent
enterokinetic activity (SmPC Prucalopride1). Serotonin (5-HT)
signaling in the gastrointestinal tract is known to regulate a
range of functions including motility and, consequently, efforts
have been made to develop selective 5-HT4 agonists for treating
disorders in which gastrointestinal motility is impaired, such
as constipation (Schiller, 2004; Galligan and Vanner, 2005).
The efficacy and safety of prucalopride has been investigated
in three pivotal, identically designed, double-blind, placebo-
controlled, phase 3, randomized clinical trials (NCT00483886,
NCT00485940, and NCT00488137) (Camilleri et al., 2008;
Quigley et al., 2009; Tack et al., 2009). European Medicines
Agency regulatory approval was based on the results of these
trials. In Europe, the Summary of Product Characteristics
(SmPC) for prucalopride states: “prucalopride (a selective, high
affinity 5-hydroxytryptamine receptor 4 [5-HT4] agonist) is
indicated for symptomatic treatment of chronic constipation in
women in whom laxatives fail to provide adequate relief” (SmPC
Prucalopride). The licensed prucalopride dose is 2mg once daily;
in women aged over 65 years, the recommended starting dose
is 1mg once daily, increasing to 2mg once daily, if required.
According to the SmPC, if once-daily prucalopride is not effec-
tive after 4 weeks of treatment, the patient should be re-examined
and the benefit of continuing treatment reconsidered.
The constipation-specific PAC-SYM and PAC-QOL measures
were used in clinical trials of prucalopride. Parker et al. exam-
ined the extent to which these measures can be mapped to two
preference-based generic instruments, the 5-Dimension EuroQol
questionnaire (EQ-5D) and the Short Form-6 Dimension ques-
tionnaire (SF-6D), to generate robust and reliable utility estimates
(Parker et al., 2011). PAC-QOL scores generated in the pivotal
clinical trials of prucalopride were converted into utility values
estimated using the EQ-5D. The 36-Item Short Form Survey (SF-
36) was also collected in the clinical trials and these data were
used to generate SF-6D estimates for comparative purposes. The
mean utility estimate at baseline for chronic constipation, based
on the EQ-5D data was 0.813 [standard deviation (SD): 0.175],
and 0.723 (SD: 0.126) when based on the SF-6D data.
1Prucalopride Summary of Product Characteristics. Available online at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_In
formation/human/001012/WC500053998.pdf (Accessed March 2015)
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An analysis by Tack et al. showed that prucalopride 2mg once
daily for 12 weeks alleviates common constipation symptoms in
women in whom laxatives had failed to provide adequate relief
(Tack et al., 2014). Given its proven effectiveness when laxa-
tives have failed to provide adequate relief (Camilleri et al., 2008;
Quigley et al., 2009; Tack et al., 2009) the cost of prucalopridemay
be justified by a favorable incremental cost-effectiveness ratio
(ICER). An economic analysis reviewed by the National Institute
for Health and Care Excellence (NICE) showed that prucalopride
was cost-effective in the UK, with the average cost per quality-
adjusted life-year (QALY) gained being e 19,728 (∼£15,700)
for prucalopride relative to continued laxative treatment (NICE
technology appraisals TA211, 2010).
The objective of the present study was to assess the cost-
effectiveness of prucalopride vs. continued laxative treatment for
chronic constipation in patients in the Netherlands in whom lax-
atives, over an extended period of time, had failed to provide
adequate relief.
Methods
In this study, a Markov model was used to estimate the cost-
effectiveness of prucalopride in a cohort of patients with chronic
constipation in the Dutch healthcare setting in 2011, when clin-
ical data were generated in the pivotal trials of prucalopride.
Data sources included published clinical trials, published Dutch
price/tariff lists, and national population statistics. The inclusion
criteria were the same as for the clinical trials of prucalopride,
and effectiveness was expressed as QALYs. The model included
relevant economic measures such as resource utilization patterns
associated with outpatient and inpatient care for patients with
chronic constipation. The primary perspective of the study was
that of the Dutch payer rather than a broader societal perspective
(Richtlijnen voor farmaco-economisch onderzoek, 2006). Costs
in the model were expressed in 2011 euros.
The model structure and the associated treatment patterns,
data sources, and assumptions were validated at a Delphi panel
meeting in Utrecht, Netherlands on 25 March 2010. The panel
consisted of seven gastrointestinal specialists and four primary
care practitioners (PCPs) working in the Netherlands who had
experience of treating chronic constipation. Sensitivity analy-
ses and scenario analyses explored uncertainty in data sources,
structure, and assumptions.
Model Design
Dutch treatment guidelines take a step-by-step approach to the
management of patients with chronic constipation (Figure 1)
(Nederlands Huisartsen Genootschap2). Initially, diet and exer-
cise are recommended, followed by use of laxatives. However,
individuals who have had chronic constipation for many years
and who fail to achieve symptomatic relief with laxatives have
limited treatment options and therefore are often switched from
one laxative to another many times, as established at the 2010
Delphi panel meeting (data on file). Dutch guidelines do not pro-
vide recommendations for switching treatments in primary care
after step 3 (Figure 1) so patients will continue to be switched to
another laxative according to the standard of care defined by the
Nederlands Huisartsen Genootschap—Dutch Society of General
Practitioners (Diemel et al., 2010).
In the UK, NICE recommendations essentially follow the
same treatment pathway, advocating a switch or the addition
of a second laxative from a different class if the first laxa-
tive does not provide adequate relief from constipation at the
maximum recommended and tolerated dose (NICE technology
appraisals TA211, 2010). NICE considered both the drug and
other medical costs of treating patients with chronic constipa-
tion when laxatives fail to provide adequate relief, and agreed
that these costs could be reduced by using prucalopride. Because
of similarities in the treatment pathways between the Nether-
lands and the UK, the Dutch model could have been based on
a similar design, population, comparator, and assumptions to
the UK model. However, this UK model included only drug
costs, whereas Dutch health economic guidelines (Richtlijnen
voor farmaco-economisch onderzoek, 2006) for the analysis of
treatment for a chronic disease require the inclusion of not only
drug costs but all direct medical costs, as well as assessment over
a long time horizon. Therefore, in the present study, a Markov
model was developed for the Netherlands that included these
additional costs and also an extended time horizon (1 year in the
base case analysis and up to 3 years in the scenario analysis). A
Markov model was chosen because this type of model is consid-
ered more transparent than the stochastic model used in the UK,
and is widely accepted by the Dutch health authorities.
Markov techniques were used to model the clinical and eco-
nomic outcomes in patients receiving prucalopride or continued
laxative treatment, allowing long-term analysis of chronic con-
stipation beyond the follow-up period in the pivotal clinical tri-
als. Figure 2 shows the structure of the model. The first branch
point was a decision node: prucalopride vs. continued laxative
treatment (standard care), and the structure of both these arms
was identical. The number of transitions allowed per cycle is
2http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samen-
vattingskaartje-NHGStandaard/M94_svk.htm
FIGURE 1 | Chronic constipation treatment pathway in the Netherlands.
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FIGURE 2 | Structure of the Markov model (p, probability; #,
1—probability). a (+) The structure for continued laxative treatment is the
same as the structure for prucalopride.
• Start week 1–4: prucalopride (or continued laxative) treatment was
started.
• Start week 5–8: prucalopride (or continued laxative) treatment was
continued after 4 weeks.
• Start week 9–12: prucalopride (or continued laxative) treatment was
continued after 8 weeks.
• Maintenance: patient was responsive to prucalopride (or continued
laxative) treatment after 12 weeks.
• Switch week 1–4: a new medication was started after failure of the initial
treatment; the initial medication was stopped. The new treatment
consisted of laxatives, in line with the 2010 Delphi panel
recommendations (described in detail in the Data Sources Section).
• Switch week 5–8: the new treatment was continued after 4 weeks.
• Switch week 9–12: the new treatment was continued after 8 weeks.
• Switch maintenance: the patient was responsive to the new treatment.
• Drop-out: patients dropped out of the model if the new (post-switch)
treatment failed, and remained drop-outs for the rest of the time horizon
of the model. The treatment for these patients also consisted of laxatives,
in line with the 2010 Delphi panel recommendations.
shown in Figure 2. The cycle length chosen for the model was
1 month, which closely approximates the intervals of measure-
ment in the three pivotal phase 3 prucalopride randomized clin-
ical trials (Camilleri et al., 2008; Quigley et al., 2009; Tack et al.,
2009). The follow-up time (analytical horizon) used in the model
was 1 year (base-case analysis).
The sequence of the initial states (weeks 1–4, 5–8, and 9–12)
was based on the design of the pivotal phase 3 trials (Camil-
leri et al., 2008; Quigley et al., 2009; Tack et al., 2009), in which
response to prucalopride and its comparator was reported after
week 4 and week 12. The model included a stopping rule that was
not applied in the clinical trials: if patients did not respond within
4 weeks, the initial prucalopride (or continued laxative) treat-
ment was discontinued and patients were switched to another
laxative. This was consistent with the cost-effectiveness model for
the UK and the NICE recommendation.
Model Assumptions
• The model did not include mortality: the time horizon of the
model in the base-case analysis was limited to 1 year and
no incremental difference in mortality was expected between
treatment groups.
• The probability of a response to a new treatment following fail-
ure of the previous one was assumed to be similar to that for
the previous treatment.
• The treatment patterns following failure of an initial treatment
were assumed to be similar to the initial pattern.
• Discontinuation during maintenance with prucalopride or
continued laxative treatment was not included.
• Modeling was performed using responses across both
sexes.
• Side effects of treatments were not included in the model
because they wereminor, transient, and assumed not to impact
on resource utilization from a payer’s perspective.
• “Normal bowel function” was used to measure the
effectiveness of treatment.
Population and Comparison
The population comprised patients with long-term functional
chronic constipation inadequately relieved by laxatives, and the
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model used data from the populations included in the pivotal
prucalopride studies (Camilleri et al., 2008; Quigley et al., 2009;
Tack et al., 2009). Altogether, the three studies included 1977
adults with similar baseline characteristics: 90% were women and
69% had had constipation for 20 years or longer. Although the
trial populations included men, the Committee for Medicinal
Products for Human Use review concluded that, based on its
risk–benefit balance, prucalopride should be licensed for symp-
tomatic treatment of chronic constipation only in women (Euro-
pean Medicines Agency3). NICE also concluded that prucalo-
pride was clinically effective in providing relief to women
with laxative-refractory chronic constipation (NICE technology
appraisals TA211, 2010). Therefore, this cost-effectiveness study
included a scenario analysis for female patients older than 18
years.
Time Horizon
Dutch guidelines recommend analysis of long-term clinical effec-
tiveness in the evaluation of healthcare technologies (Richtlijnen
voor farmaco-economisch onderzoek, 2006); the base-case analy-
sis therefore assumed a 1-year follow-up period. The pivotal clin-
ical trials for prucalopride covered a period of 12 weeks; however,
long-term observational data (Camilleri et al., 2010) concerning
patient satisfaction were collected, which showed that, between
week 12 and week 52, patients experienced no significant changes
in the efficacy of prucalopride. These data were used to extend the
time frame in the model to 12 months.
Effectiveness and Economic Outcomes
The primary analysis was a cost–utility analysis in line with
Dutch health economic guidelines (Richtlijnen voor farmaco-
economisch onderzoek, 2006), and the primary outcome mea-
sure was incremental cost per QALY gained.
Medical costs reflected the resource utilization associated with
treatment of chronic constipation and its complications. The
costs of over-the-counter laxatives were not included, because
individuals with chronic constipation are treated within the med-
ical setting (e.g., by their primary care physician [PCP] or a
specialist), and therefore reimbursed laxatives are prescribed. A
scenario analysis was performed including indirect costs due to
productivity loss derived from international studies, as no Dutch
data on these costs were available.
Because the time horizon of the base-case analysis was 1 year,
discounting was not applied. A 3-year scenario analysis was
conducted, however, using discount rates of 4% for economic
outcomes and 1.5% for clinical outcomes, in line with Dutch
guidelines (Richtlijnen voor farmaco-economisch onderzoek,
2006).
Sensitivity and Scenario Analysis
Sensitivity analyses were performed on:
• Response to prucalopride at week 4
• Response to prucalopride at week 12
3CHMPASSESSMENTREPORT FORResolor. www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Public_assessment_report/human/001012/WC50005
3997.pdf
• Diagnose Behandel Combinatie (DBC) hospitalization
• DBC specialist consultation
Scenario analyses were performed on:
• Response for women only
• Response based on the PAC-QOL patient satisfaction subscale
• Excluding the stopping rule at 4 weeks
• Excluding cost of complications
• Using an average daily dose of 1.5mg for prucalopride rather
than the 2mg daily dose used in the base-case analysis
• Including indirect costs due to lost productivity
• Excluding transportation costs
• Using hospital costs based on daily costs and length of stay
rather than the Dutch diagnosis treatment code list fixed price
• A time horizon of 3 years instead of 1 year
• Including the effect of mortality
• Inflating costs to 2014 values
Data Sources
Clinical Data
Tables 1–4 provide an overview of the clinical data for the
Markov model, based on pooled information from the piv-
otal phase 3 trials; these data were also used in the UK cost-
effectiveness model (Camilleri et al., 2008; Quigley et al., 2009;
TABLE 1 | Number (%) of patients with three or more spontaneous
complete bowel movements per week.
Time point Placebo Prucalopride 2mg Prucalopride 4mg
(N = 645; F = 580) (N = 640; F = 566) (N = 639, F = 558)
n (%) n (%) n (%)
WEEKS 1–12
All 73 (11.3) 151 (23.6)* 158 (24.7)*
Female 62 (10.7) 138 (24.4)* 136 (24.4)*
WEEKS 1–4
All 68 (10.5) 178 (27.8)* 192 (30.0)*
Female 58 (10.0) 166 (29.3)* 169 (30.3)*
Pooled data from the intent-to-treat population in the pivotal prucalopride clinical trials
(Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009) (F, female). *P < 0.001 vs.
placebo (pairwise comparison).
TABLE 2 | Number (%) of patients with at least 1 point improvement on the
satisfaction subscale of the Patient Assessment of Constipation Quality
of Life instrument.
Time point Placebo Prucalopride Prucalopride
(N = 645) 2mg (N = 640) 4mg (N = 639)
N n (%) N n (%) N n (%)
Week 12a 618 137 (22.2) 621 273 (44.0)* 603 261 (43.3)*
Week 4a 605 129 (21.3) 598 271 (45.3)* 588 270 (45.9)*
Pooled data from the intent-to-treat population in the three pivotal prucalopride clinical tri-
als (Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009). aLast observation carried
forward. *P < 0.001 vs. placebo (pairwise comparison).
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TABLE 3 | Delphi panel estimates of the probabilities of a response after
switching treatment to prucalopride, treatment practices after treatment
failure, and complications in patients after treatment for chronic
constipation or a switch in treatment to prucalopride (PCP, primary care
physician).
Probability (%)
TREATMENT SWITCH
Response after switching treatment 65.4
TREATMENT PRACTICE AFTER FAILURE
Referral to specialist by PCP 28.2
Hospitalization 4.9
No referral or hospitalization 66.9
Probability of complications Weeks 1–4 Weeks 5–12 Switch
Hemorrhoids 19.0 22.0 12.0
Anal fissures 7.0 11.0 6.0
Fecal incontinence 8.0 7.0 6.0
External peri-anal thrombosis 7.0 9.0 2.0
Rectal prolapse 3.4 5.0 0.8
Fecal impaction 14.1 15.4 3.8
TABLE 4 | Utilities for the different health states in the model.
Utility
PRUCALOPRIDE
Starting treatment (weeks 1–4) 0.786
Continuing treatment after 4 weeks (weeks 5–8) 0.813
Continuing treatment after 8 weeks (weeks 9–12) 0.813
Responders to prucalopride (> 12 weeks) 0.890
CONTINUED LAXATIVE TREATMENT
Starting treatment (weeks 1–4) 0.781
Continuing treatment after 4 weeks (weeks 5–8) 0.805
Continuing treatment after 8 weeks (weeks 9–12) 0.805
Responders to continued laxative treatment (> 12 weeks) 0.879
SWITCH
Starting treatment with a new treatment (weeks 1–12) 0.784
Responders to switch treatment (> 12 weeks) 0.879
Drop-out 0.784
Tack et al., 2009). The primary cost-effectiveness analysis was
based on the intent-to-treat population. Placebo response was
used as a proxy for response to laxatives in patients with chronic
constipation; this was supported by a meta-analysis that showed
poor evidence for sustained benefit with laxatives (Jones et al.,
2002).
The pivotal trials demonstrated that men respond to prucalo-
pride in a similar way to women; however, given the small num-
ber of men in the trials, no significant difference in efficacy
was demonstrated between prucalopride and placebo. Modeling
was performed using responses across both sexes, because the
utility mapping applied to the entire trial population. Because
the utilities in this model are based on empirical mapping
between PAC-QOL and EQ-5D for the entire trial popula-
tion (see the Utilities Section), we decided to use the effi-
cacy data from the entire trial population in the base-case
analysis. A separate scenario analysis was performed to con-
sider women only (the target population) in order to ascer-
tain the uncertainty associated with the assumption that men
would respond similarly to women. One recent publication
has shown that the efficacy of prucalopride is similar in
the intent-to-treat population and the target population (Tack
et al., 2013), while the results of another clinical trial have
shown that efficacy is similar in men and women (Ke et al.,
2012).
The base-case analysis was based on the primary clinical out-
come from the pivotal trial. Response was defined as the propor-
tion of patients who achieved “normal bowel function” within
the 4-week and 12-week periods; normal bowel function was
defined as a mean of three or more spontaneous and complete
bowel movements per week. The response rate after 4 weeks was
10.5% for placebo, 27.8% for prucalopride 2mg once daily, and
30.0% for prucalopride 4mg once daily, and after 12 weeks was
11.3% for placebo, 23.6% for prucalopride 2mg once daily, and
24.7% for prucalopride 4mg once daily (Table 1). The base-case
analysis was based on prucalopride 2mg once daily and so data
for this dose from the clinical trials were used.
A scenario analysis used the PAC-QOL patient satisfaction
subscale (Table 2) as the primary quality of life parameter. One
point on this subscale was the predefined threshold for a clini-
cally meaningful response; this is twice the minimal important
difference (0.5) (Dubois et al., 2010).
Probabilities of response after switching to another treat-
ment were also included in this study. These data were not
available in the published literature; therefore, probabilities esti-
mated by the 2010 Dutch Delphi panel were used (data on file)
(Table 3).
Table 3 also provides the 2010 Dutch Delphi panel’s estimates
for probabilities of complications of constipation. Singh et al.
showed the probability of such complications using a California
Medicaid database (Singh et al., 2007), reporting a 2.05% prob-
ability of fecal impaction; the probability reported by the 2010
Dutch Delphi panel was 14.1% at the start of treatment. However,
the Singh et al. study related to patients newly diagnosed with
constipation in a single state in the USA; therefore the Dutch Del-
phi estimates were considered more appropriate than the Singh
data for a population in the Netherlands with chronic constipa-
tion. The estimates made by the Delphi panel were adjusted to
monthly probabilities in order to correspond with the cycle time
of the model.
Utilities
Empirical mapping of PAC-QOL scores to EQ-5D scores pro-
vided data on utilities for patients using prucalopride or con-
tinued laxative treatment. Pooled data from the pivotal phase
3 studies provided response and overall PAC-QOL outcomes
(Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009).
Parker et al. used statistical methods to identify a mapping func-
tion to assess the extent to which changes in generic HRQoL can
be “explained” by more condition-specific measures, these were
used in the UK cost-effectiveness model (Parker et al., 2011; Tack
et al., 2014). A relationship was determined between PAC-QOL
and EQ-5D.
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TABLE 5 | Resource utilization of patients with chronic constipation who did not obtain adequate relief from laxatives, determined by the Delphi processa
(GI, gastrointestinal; PCP, general practitioner).
Number per month
Weeks 1–4 Weeks 5–12 Maintenance Switch weeks 1–4 Switch maintenance
CONSULTATIONS
Specialist consultation 0.6 0.6 0.4 0.8 0.3
Specialist telephone call 0.3 0.6 0.4 0.4 0.1
PCP consultation 0.9 1.0 0.7 0.7 0.6
PCP telephone call 0.6 1.1 0.5 0.3 0.3
Nurse consultation 0.2 0.2 0.2 0.2 0.1
Dietician consultation 0.1 0.2 0.3 0.2 0.1
PROCEDURES
Colonoscopy/gastroscopy 0.6 0.5 0.4 0.4 0.2
Digital rectal examination 0.8 0.6 0.4 0.6 0.3
Anoscopy/proctoscopy 0.2 0.5 0.1 0.2 0.2
Blood tests 0.8 0.9 0.5 0.0 0.0
Radiograph 0.2 0.7 0.5 0.3 0.1
GI transit 0.2 0.0 0.0 0.2 0.1
Evacuation/Fleet® enema 0.3 0.6 0.5 0.2 0.0
aAs per the Delphi survey, resource use applies to a patient population with chronic constipation not adequately relieved by laxatives and seeking medical care for their continuing
condition and likely complications.
The model developed by Parker et al. stratifies patients as
responders and non-responders to prucalopride (or continued
laxative) treatment. Therefore, PAC-QOL scores were deter-
mined separately for responders and non-responders. Table 4
provides a list of utilities for the Markov model based on this
mapping study. These are in line with the utilities used in a pre-
vious cost-effectiveness model comparing macrogol and lactu-
lose in the treatment of patients with chronic constipation: 0.06
monthly utility for symptomatic states and 0.07 monthly util-
ity for well-controlled states, corresponding to annual utilities of
0.72 and 0.84, respectively (Taylor and Guest, 2010).
For patients in whom initial treatment failed, or those who
were switched to another medication, the same average base-
line utility based on the placebo and prucalopride arms was
used. This is a conservative assumption since, if a patient
is not improving, their utility could decline to the placebo
level.
Resource Utilization
The medication costs for continued laxative use and for other
treatments were derived from the distribution of the various
types of medication and their dosages, as reported by the 2010
Delphi panel, and published Dutch list prices (Farmacothera-
peutisch Kompas).
The non-drug resource utilization for each health state was
programmed as a monthly cost. The following were included:
the management of chronic constipation; the additional resource
utilization associated with a change of therapy after a fail-
ure; and the additional resource utilization resulting from
complications.
Because published data on such resource use were limited, the
2010 Delphi panel’s estimates were used (Tables 5, 6).
TABLE 6 | Resource use related to complications per patient with chronic
constipation who did not obtain adequate relief from laxatives,
determined by the Delphi processa (PCP, primary care physician).
Number of Proportion of cases with
consultations per month hospitalization
PCP Specialist % Duration of
stay (days)
Hemorrhoids 2.2 1.5 1.7 1.0
Anal fissures 2.3 1.0 1.7 3.0
Fecal incontinence 1.8 1.6 8.9 4.5
External peri-anal
thrombosis
2.0 1.1 5.6 1.7
Rectal prolapse 1.2 1.7 36.7 5.2
Fecal impaction 1.8 1.2 16.2 3.0
aAs per the Delphi survey, resource use applies to a patient population with chronic con-
stipation not adequately relieved by laxatives and seeking medical care for their continuing
condition and likely complications.
Costing
The following costs were included in the model (Table 7).
• Annual drug costs were derived from published Dutch
list prices (Farmacotherapeutisch Kompas4) based on rec-
ommendations in the Dutch Costing Manual (Handleiding
voor kostenonderzoek, 2010). The cost of continued laxa-
tive treatment was derived from a weighted average based
on distribution recommended by the 2010 Delphi panel. For
prucalopride, the base-case analysis was based on 2mg daily
4https://www.farmacotherapeutischkompas.nl/
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TABLE 7 | Costing information included in the Markov model (CBS, Centraal Buro Satistiek; DBC, Diagnose Behandel Combinatie [Dutch diagnosis
treatment code]; PCP, primary care physician; NZa, Nederlandse Zorgautoriteit [Dutch health authority].
Dose First pack (28 days) After 28 days Data source Costing year
Prucalopride 1mg e 1.95 per day e 1.62 per day Shire-Movetis 2010
2mg e 2.77 per day e 2.49 per day Shire-Movetis 2010
Pack size Cost per pack Distribution start (switch)a Daily dose Daily cost Costing year
SOURCE: FARMACOTHERAPEUTISCH KOMPAS
Movicolon® sachets 1 sachet e 0.32 42% (27%) 1.5 sachet e 0.48 2010
Bisacodyl 5mg e 0.11 8% (17%) 7.5mg e 0.17 2010
Forlax® 10g e 0.61 15% (7%) 10 g e 0.61 2010
Metamucil® 1 sachet e 0.30 18% (23%) 2 sachets e 0.60 2010
Lactulose 10 g e 0.23 17% (0%) 10mg e 0.23 2010
Magnesium oxide 500mg e 0.03 0% (26%) 3.5 g e 0.21 2010
Prescription rule e 6.35
Cost/unit Data source Costing year
PCP e 28.00 Costing manual 2009
Specialist e 72.00 Costing manual 2009
PCP telephone call e 14.00 Costing manual 2009
Nurse e 10.00 Costing manual 2009
Nurse telephone call e 0.00 Costing manual 2009
Dietician e 27.00 Costing manual 2009
DBC: polyclinic for constipation e 195.89 DBC 1337101b (NZa tarieven) 2010
DBC: hospitalization for constipation e 3102.00 DBC 141508 (NZa tarieven) 2010
Inflation rate Data source Costing year
2009 1.2% CBS 2009
2010 1.3% CBS 2010
aDistribution of laxatives at start (and after switching) of therapy.
bSee Supplementary Material.
for a maximum period of 220 days per year according to
clinical data. A scenario analysis was performed on 1.5mg
prucalopride daily, assuming a 50% divide between 1 and 2mg
daily dose and similar effectiveness in a daily practice setting.
• A stopping rule was applied as follows: if once-daily prucalo-
pride was not effective after 4 weeks of treatment according
to the SmPC, prucalopride was discontinued. The drug costs
and Dutch prescription rule (“receptregel”) included 6% value
added tax; the prescription rule means that there is a fixed fee
for each prescription dispensed by the pharmacist.
• Based on long-term trial data, the average annual cost assumed
that, in clinical practice, the average duration of use of prucalo-
pride in the maintenance phase was 130 days per year in
the first year and 220 days in the second and third years
(NICE technology appraisals TA211, 2010). The maximum
annual period of treatment was 220 days and therefore, after
the initial period of 3 months (90 days), 130 treatment days
were left in the first year. This was consistent with the UK
cost-effectiveness model.
• PCP consultation tariffs were derived from the Dutch Costing
Manual.
• Costs of outpatient visits to specialists were based on the Dutch
Diagnosis Behandel Combinatie (diagnosis treatment code)
list (which assumes a fixed overall cost for a specialist con-
sultation). The analysis was based on a minimum value of
e 195.89.
• Hospitalization costs were based on the Dutch diagnosis
treatment code list (which assumes a fixed overall cost
for a hospitalization). The analysis was based on a mini-
mum value of e 3102 (in a scenario analysis, costs were
calculated by the product of length of stay and daily
cost).
• Non-medical direct costs were calculated based on the
following average distances: 1.1 km to the PCP’s surgery,
7.0 km to the specialist and to the hospital, and 1.7 km
to the dietitian. These distances were multiplied by cost
per kilometer of e 0.20, which was similar whether driv-
ing or taking public transport (year of costing 2009, inflated
to 2011). The base-case analysis was based on transporta-
tion costs only, excluding parking costs. A scenario analy-
sis also included additional costs of e 3.00 for parking, if
driving.
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Indirect Costs
Indirect costs were calculated using the methodology described
in the Dutch Manual for Costing and recent economic data from
the main Dutch national statistical data source to reflect the
patient population treated (Handleiding voor kostenonderzoek,
2010). As mentioned earlier, indirect costs were not included
in the base-case analysis owing to lack of Dutch data on lost
productivity. A scenario analysis was therefore performed using
international data. A survey in 2007 showed that 12% of respon-
dents who worked or attended school reported missing a mean of
2.4 days per month from work or class because of chronic consti-
pation symptoms (Johanson and Kralstein, 2007). The mean cost
per hour lost was e 26.99 and the mean annual number of work-
ing hours lost was 1540 (Handleiding voor kostenonderzoek,
2010). The overall pooled percentage of patients aged between 18
and 65 years was 87.0% (European Medicines Agency).
Results
Base-Case Analysis
The base-case analysis indicated that the total cost of treatment
over a period of 1 year with prucalopride was e 2511 per patient,
compared with e 2446 per patient for continued laxative treat-
ment (Table 8). The average patient treated with prucalopride
gained 0.833 QALYs, compared with 0.826 for those on con-
tinued laxative treatment. The ICER for prucalopride treatment
relative to continued laxative treatment was e 9015 per QALY
gained.
Scenario Analyses
The results of the scenario analyses are presented in the Supple-
mentary Material.
Sensitivity Analyses
In addition to these scenario analyses, the sensitivity of
the base-case results to a range of key parameters was
assessed.
One-Way Sensitivity Analyses
Results of one-way sensitivity analyses (shown in Figure 3, with
detailed results in Table 9) showed that the model is sensitive to
the response to prucalopride. The ICER varied from e 6475 to
15,380 per QALY gained for response at week 4, and frome 7267
to 14,657 per QALY gained for response at week 12. The analyses
showed that themodel wasmoderately sensitive to Dutch diagno-
sis treatment code values. The ICER varied frome 7662 to 10,369
TABLE 8 | Results of the base-case analysis indicating the costs, QALYs,
and ICER associated with prucalopride vs. continued laxative treatment
for chronic constipation (ICER, incremental cost-effectiveness ratio;
QALY, quality-adjusted life-year).
Costs QALYs ICER
Prucalopride e 2511 0.833
Continued laxative treatment e 2446 0.826
Difference e 65 0.007 e 9015
per QALY gained for hospitalization, and from e 7305 to 10,726
per QALY gained for consultation.
Probabilistic Sensitivity Analysis
A probabilistic sensitivity analysis was performed to explore the
uncertainty in the estimates of the input parameters. Resource
use quantities were assumed to follow gamma distributions, while
utilities and probabilities were assumed to follow beta distribu-
tions (Briggs, 2000; Briggs et al., 2002). The analysis was based
on 5000 patients. Empirically, a plateau to 1 was reached from
4000 onward. The standard deviation did not change from 4000
TABLE 9 | Costs and QALYs associated with a response to prucalopride
determined by sensitivity analyses (CI, confidence interval; DBC,
Diagnose Behandel Combinatie [Dutch diagnosis treatment code]; ICER,
incremental cost-effectiveness ratio; QALY, quality-adjusted life-year).
Costs (e) QALYs ICER
RESPONSE TO PRUCALOPRIDE (4 WEEKS) (BASE CASE: 27.8%)
Minimum: 24.4% (2.5% CI)
Prucalopride 2525 0.831
Continued laxative treatment 2446 0.826
Difference 79 0.005 15,380
Maximum: 31.4% (97.5% CI)
Prucalopride 2501 0.835
Continued laxative treatment 2446 0.826
Difference 56 0.009 6475
RESPONSE TO PRUCALOPRIDE (12 WEEKS) (BASE CASE: 23.6%)
Minimum: 20.4% (2.5% CI)
Prucalopride 2528 0.832
Continued laxative treatment 2446 0.826
Difference 82 0.006 14,657
Maximum: 25.0% (97.5% CI)
Prucalopride 2503 0.834
Continued laxative treatment 2446 0.826
Difference 57 0.008 7267
DBC: HOSPITALIZATION
Minimum: 25% lower
Prucalopride 2452 0.833
Continued laxative treatment 2377 0.826
Difference 75 0.007 10,369
Maximum: 25% higher
Prucalopride 2570 0.833
Continued laxative treatment 2514 0.826
Difference 55 0.007 7662
DBC: CONSULTATION SPECIALIST
Minimum: 25% lower
Prucalopride 2146 0.833
Standard care 2068 0.826
Difference 77 0.007 10,726
Maximum: 25% higher
Prucalopride 2876 0.833
Standard care 2823 0.826
Difference 53 0.007 7305
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FIGURE 3 | Tornado diagram of incremental cost-effectiveness ratios of prucalopride relative to continued laxative use determined by one-way
sensitivity analyses (DBC, Diagnose Behandel Combinatie [Dutch diagnosis treatment code]; ICER, incremental cost-effectiveness ratio).
FIGURE 4 | (A) Cost-effectiveness acceptability plot for the base-case analysis. (B) Scatter plot showing the cost-effectiveness estimates for the base-case analysis
(ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life-year).
cycles onward. The ICERwase 8892 per QALY gained compared
with e 9015 in the base-case analysis.
The cost-effectiveness acceptability plot shown in Figure 4A
reflects the probability that each treatment is the most cost-
effective treatment considered in the analysis at a range of differ-
ent threshold ICER values. The results indicate there is a greater
than 80% probability that prucalopride is more cost-effective
than continued laxative treatment, if Dutch society is willing to
pay at least e 20,000 per QALY gained. Figure 4B shows the
incremental outcomes for costs and QALYs resulting from the
probabilistic sensitivity analysis.
Discussion and Conclusion
The base-case model revealed that prucalopride 2mg once daily
is a cost-effective option for patients with chronic constipation in
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the Netherlands, costinge 9015 per QALY gained relative to con-
tinued laxative treatment. Extensive scenario analyses and sensi-
tivity analyses underlined the robustness of the base-case result.
In these analyses, keymodel parameters were varied substantially.
In the scenario analysis examining the response in women only,
the label target population, the ICER decreased from e 9015 to
7773 per QALY gained.
In this context, it is noteworthy that this cost-effectiveness
model included information from three large international piv-
otal trials (Camilleri et al., 2008; Quigley et al., 2009; Tack et al.,
2009), showed a consistent response for multiple endpoints, and
involved a trial population similar to the patient population in
clinical practice.
Defining the response in terms of frequency of bowel move-
ments does not encompass all aspects of efficacy. For this reason,
patient satisfaction reflects the efficacy of prucalopride in clin-
ical practice better than the primary outcome measure in the
pivotal clinical trials, which was used in the base-case analysis
(i.e., three or more spontaneous complete bowel movements per
week). The predefined primary HRQoL endpoint dimension of
the PAC-QOL was therefore used in a scenario analysis, resulting
in a decrease in ICER frome 9015 to 5197 per QALY gained. The
clinical relevance of satisfaction in chronic constipation has been
shown in a study by Müller-Lissner et al. (2010).
Owing to a lack of solid Dutch data, indirect costs were
excluded from the base-case model. A scenario analysis included
lost productivity based on international data on working
days lost, resulting in a decrease in ICER from e 9015 to
5228 per QALY gained. Hence, the base-case analysis was
conservative.
The use of a Delphi panel to establish resource utilization
data when no such data exist is accepted methodology according
to Dutch health economic guidelines (Richtlijnen voor farmaco-
economisch onderzoek, 2006). The proportion of complications
in patients with chronic constipation was also estimated by the
Delphi panel owing to a lack of data. Exclusion of such com-
plications from the analysis resulted in an increase in ICER
from e 9015 to 12,216 per QALY gained; therefore, prucalopride
remained cost effective when complications were not considered.
The time horizon of the model was only 1 year because of a
lack of long-term data. However, a scenario analysis over a 3-
year period confirmed the robustness of the outcome: the ICER
decreased frome 9015 to 4436 per QALY gained, illustrating that
the 1-year results probably underestimate the cost-effectiveness
of prucalopride.
In the Netherlands, the threshold for a drug to be considered
cost-effective varies from e 10,000 to 80,000 per QALY gained,
depending on the severity of the disease. Extensive scenario and
sensitivity analyses underlined the robustness of the base-case
cost-effectiveness of prucalopride.
In Europe, registration of prucalopride is for women for
whom laxative treatment has failed, whereas the pivotal trials
included both men and women, and the mapping of utilities
was performed using the clinical outcomes for this total popu-
lation. A scenario analysis considering only women confirmed
the robustness of this approach, because the ICER decreased only
from e 9015 to 7773 per QALY gained. The base-case analysis
was therefore conservative.
In the UK cost-effectiveness model, the patient population
was created by bootstrapping (re-sampling) a repeated random
draw from the 1462 patients in the pivotal trials by age category,
using the age and corresponding baseline severity (EQ-5D utility
score) distributions defined by these 1462 patients. A cohort of
38,650 patients was found to be sufficient to reduce the variabil-
ity (sampling error) and provide a stable outcome in the model,
and therefore this formed the basis for the cost–utility analysis
of the use of prucalopride in the Netherlands. It is important to
note that the bootstrap was performed only to create the model’s
population, and was not used in the regression analyses or in the
mapping process, for which actual observations were used. This
population allows the analysis of all women (18 years or older) as
well as of other subgroups.
There were a number of reasons to develop a Markov model
for the Netherlands. Dutch health economic guidelines require
the inclusion of all medical costs, whereas the UK model con-
sidered only drug costs. Another reason for choosing a Markov
model was to enable long-term analysis beyond the clinical
trial period, in line with Dutch guidelines for pharmacoeco-
nomic research (Richtlijnen voor farmaco-economisch onder-
zoek, 2006). Increasing the time horizon to 3 years instead of 1
year resulted in a decrease in the ICER; consequently the 1-year
time horizon may underestimate the true cost-effectiveness of
prucalopride.
The current study used placebo response as a proxy for the
response to laxatives in patients with chronic constipation. An
alternative option would have been to use another laxative as a
comparator. In this case it was decided not to use that approach,
as there is a lack of clinical evidence for sustained benefit with lax-
atives (Jones et al., 2002). Nevertheless, future studies may wish
to consider this.
The published pharmacotherapeutic report on prucalopride
by the Medicinal Products Reimbursement Committee (CFH)
indicated a negative opinion in their evaluation (approved
26 November 2012). The main criticism of the CFH was the asso-
ciation between the defined patient population and the clinical
evaluation. The report explained that it was unclear whether the
patients included in the studies were refractory to optimum doses
of standard laxatives. Nevertheless, in clinical practice, physi-
cians will generally take into account the balance between efficacy
and tolerance in each patient that they treat. Therefore, health-
care practitioners will not always prescribe the maximum rec-
ommended dose, and the positive cost-effectiveness benefits of
prucalopride in the Netherlands should still be valid.
Besides the positive cost-effectiveness benefits of prucalopride
for the Dutch payer and society, prucalopride also has a positive
impact on patients with chronic constipation. Prucalopride treat-
ment increases not only the number of spontaneous complete
bowel movements but also patient satisfaction and HRQoL.
Finally, the study estimated the cost-effectiveness of prucalo-
pride in the Dutch healthcare setting in 2011. The reason for
choosing this date was that this was when clinical data were
generated in the pivotal trials of prucalopride. Inflating costs to
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2014 values did not significantly change the ICER of prucalopride
relative to continued laxative treatment.
Conclusion
In terms of cost per QALY gained, prucalopride was cost-effective
in Dutch patients with chronic constipation that was inade-
quately relieved by the use of laxatives, as shown by a conservative
base-case analysis using a Markov model. Extensive sensitivity
analyses and scenario analyses underlined the robustness of the
base-case cost-effectiveness.
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